Groupe Novasep merger completes

Related tags Groupe novasep Analytical chemistry Chemical engineering

The marriage between US chemicals group Dynamic Synthesis and
French separations specialist Novasep has been completed, creating
what the new company claims is a unique company to serve the life
sciences industry.

Groupe Novasep is offering proprietary separation technologies along with fine chemicals, and will provide development services, separation systems or contract manufacturing using chemistry, chromatography or a combination of the two. To date, Novasep has focused finding purification solutions by the research and development of new purification processes as well as active pharmaceutical ingredient (API) production.

Roger-Marc Nicoud, the founder and CEO of Novasep who has assumed the role of president and CEO of the new company, believes that the combined entity will answer the changing dynamics of the life sciences marketplace.

"Customers demand higher purity levels, cost efficient solutions, strict regulatory and operational controls, and shorter times to market. Our vision for the new company is to be the integrated and innovative resource customers count on to meet all of these requirements,"​ he said.

Groupe Novasep is now composed of the following companies: Applexion (bioseparations); Dynamit Nobel Special Chemistry (hazardous chemistry); Finorga (fine chemistry); Novasep (separation processes); Orelis (membranes); Rohner (fine chemistry); and Seripharm (fine chemistry and cytotoxic products).

The new Groupe Novasep would have had combined revenues in 2003 of approximately €300 million and 1,500 employees, serving customers worldwide through its European facilities in France, Germany and Switzerland and branch locations in North America and Asia.

Dynamic Synthesis was formerly part of Rockwood Specialties, which acquired the Dynamit Nobel business from mg technologies of Germany.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more